Radiopharmaceuticals as Novel Immune System Tracers

Area of Science:

• Oncology
• Immunology
• Radiopharmaceuticals

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but benefit only a subset of patients.
• Optimizing patient selection and response assessment is crucial for improving ICI efficacy.
• Noninvasive imaging offers a potential solution for real-time evaluation of immune responses.

Purpose of the Study:

• To review the rationale and current status of noninvasive molecular imaging for assessing the PD-1/PD-L1 axis in cancer immunotherapy.
• To highlight the potential of PD-L1 immuno-PET as a biomarker for patient selection and response monitoring.
• To provide insights for future clinical trials and therapeutic regimen design.

Main Methods:

• Review of preclinical and clinical studies on PD-L1 immuno-positron emission tomography (immuno-PET).
• Discussion of immunoconjugate radiopharmaceuticals for assessing cell surface immune markers.
• Exploration of molecular imaging strategies for immune checkpoint biomarkers.

Main Results:

• Noninvasive immuno-PET can provide a quantitative, real-time assessment of PD-L1 expression, akin to a virtual biopsy.
• Immuno-PET has the potential to guide patient selection for ICI therapy.
• Current research indicates promising applications for PD-L1 immuno-PET in various cancers.

Conclusions:

• Immune checkpoint imaging, particularly PD-L1 immuno-PET, holds significant promise as a biomarker for immunotherapy.
• This technology can enhance patient stratification and enable personalized treatment strategies.
• Future research should focus on integrating immune imaging into clinical trials for ICI and combination therapies.